Muscle & nerve · 2026
Efficacy of a K+ Channel Agonist, XEN1101, For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chanchykov Viktor, Iype Sharon, Quinonez Marbella, Wu Fenfen, Cannon Stephen
Аннотация
INTRODUCTION/AIMS: Effective management remains lacking for recurrent episodes of acute weakness in hypokalemic periodic paralysis (HypoPP). We assessed the efficacy of a second-generation potassium channel agonist, XEN1101, to prevent and abort the low-K+ induced loss of force in mouse models of HypoPP.
METHODS: An ex vivo contractility assay was used to interrogate the efficacy of XEN1101 for preserving contractile force and for enhancing recovery of force in the setting of a low-K+ challenge for HypoPP mice carrying the sodium channel NaV1.4-R669H or the calcium channel CaV1.1-R528H mutations.
RESULTS: The acute loss of force for HypoPP muscle, triggered by a 2 mM K+ challenge, was prevented by low micromolar XEN1101, with an effective concentration of 0.30 μM for 50% protection. Application of 1 μM XEN1101, after the onset of 2 mM K+ induced weakness, restored the peak contractile force (70%-100% of baseline).
DISCUSSION: The KV7 potassium channel agonist XEN1101 is effective as both a prophylactic agent and as abortive therapy for management of low-K+ induced weakness in murine models of HypoPP. XEN1101 is more potent than the first-generation Kv7 agonist, retigabine, in our murine models of HypoPP and is also better tolerated in patients. These improvements provide a rationale for future clinical trials of XEN1101 in HypoPP patients.
METHODS: An ex vivo contractility assay was used to interrogate the efficacy of XEN1101 for preserving contractile force and for enhancing recovery of force in the setting of a low-K+ challenge for HypoPP mice carrying the sodium channel NaV1.4-R669H or the calcium channel CaV1.1-R528H mutations.
RESULTS: The acute loss of force for HypoPP muscle, triggered by a 2 mM K+ challenge, was prevented by low micromolar XEN1101, with an effective concentration of 0.30 μM for 50% protection. Application of 1 μM XEN1101, after the onset of 2 mM K+ induced weakness, restored the peak contractile force (70%-100% of baseline).
DISCUSSION: The KV7 potassium channel agonist XEN1101 is effective as both a prophylactic agent and as abortive therapy for management of low-K+ induced weakness in murine models of HypoPP. XEN1101 is more potent than the first-generation Kv7 agonist, retigabine, in our murine models of HypoPP and is also better tolerated in patients. These improvements provide a rationale for future clinical trials of XEN1101 in HypoPP patients.